Pharming Group N.V. secured regulatory approval in Japan for its oral PI3K‑delta inhibitor, Joenja (leniolisib), for the treatment of activated PI3K‑delta syndrome (APDS) in patients aged four years and older. The Ministry of Health, Labour and Welfare granted the approval on March 24, 2026, making Joenja the first targeted therapy for APDS available in Japan and the first drug approved worldwide for children 4‑11 with the condition.
The approval was based on robust Phase III data from multinational and Japanese studies that demonstrated significant reductions in lymphadenopathy and increases in naïve B‑cell percentages, confirming the drug’s efficacy in a pediatric population that previously had no disease‑specific treatment options.
Pharming will partner with Japanese orphan‑drug specialist OrphanPacific, Inc. to serve as the marketing‑authorization holder, supply, and distribution partner. Pricing negotiations with the National Health Insurance system are underway, and the launch is expected shortly after a final price is set.
The Japanese entry expands Joenja’s addressable market beyond the United States and United Kingdom, where the drug is already approved for patients 12 and older. The approval is expected to contribute to Pharming’s 2026 revenue guidance of US$405–425 million and supports the company’s strategy to broaden its rare‑disease portfolio and pursue additional regional approvals.
Leverne Marsh, Chief Commercial Officer, said, “The approval of Joenja for patients as young as 4 years of age is an important milestone for the APDS community in Japan. As the first treatment approved specifically for APDS in the country, it is the only targeted treatment option for patients and families affected by this rare and progressive disease. Together with OrphanPacific, we look forward to working through the next steps to help make Joenja available to patients in Japan as quickly as possible.” Professor Hirokazu Kanegane added, “Patients with APDS in Japan have until now relied largely on supportive care, so this approval marks an important step forward for the APDS community. This approval introduces the first approved targeted treatment option for this rare primary immunodeficiency in Japan, and has the potential to help reduce the burden of disease for patients and their families.”
The approval underscores Pharming’s growing presence in the rare‑disease market and positions the company to accelerate future approvals in other regions, potentially doubling the addressable market for Joenja.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.